SAN DIEGO, Sept. 2, 2015 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, announced
today that members of its leadership team will be making
presentations at several high-profile events in September,
including:
- First World Congress on Electroporation and Pulsed Electric
Fields in Biology, Medicine and Food & Environmental
Technologies; Portoroz, Slovenia
- Rodman & Renshaw 17th Annual Global Investment Conference;
New York, NY
- Second Annual Global Summit on Practical and Emerging Trends in
Melanoma; Pasadena, CA
- European Cancer Congress 2015; Vienna, Austria
- Sachs 15th Annual Biotech in Europe Forum; Basel, Switzerland
First World Congress on Electroporation and Pulsed Electric
Fields in Biology, Medicine and Food & Environmental
Technologies
Robert H.
Pierce, MD, Chief Scientific Officer, will present a keynote
lecture entitled: "Advances in Clinical Electroporation: Tissue
Sensing, Feedback Control, and Catheter Technology" at the First
World Congress on Electroporation and Pulsed Electric Fields on
September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in
Portorož, Slovenia. OncoSec will
also be presenting a poster entitled: "Development of a
Catheter-Based Applicator for Immuno-Oncology."
Richard Heller, PhD, member of
OncoSec's Scientific Advisory Board and Professor at the School of
Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture
during the "Medical Applications: Gene Therapy" session on
September 9 entitled: "Effective
Enhancement of Immune Response Utilizing Gene
Electro-Transfer."
Adil Daud, MD, member of
OncoSec's Melanoma Advisory Board and Professor of Medicine at the
University of California, San
Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with
Plasmid IL-12 Electroporation in Melanoma and Merkel Cell
Cancer."
This meeting brings together individuals possessing diverse
expertise, who are involved in basic research or are developing
applications based on electroporation and the use of pulsed
electric fields of high intensity. The aim is to create a
stimulating interdisciplinary environment to present the latest
achievements and demonstrate current knowledge in this rapidly
advancing field. For more information, please visit:
https://wc2015.electroporation.net.
Rodman & Renshaw 17th Annual Global Investment
Conference
Punit Dhillon,
President and CEO, will present a corporate overview at the Rodman
& Renshaw 17th Annual Global Investment Conference on
September 9 at 10:00 AM ET at the St. Regis Hotel in
New York City. To view and listen
to the live webcast, please access the following link at the time
of the presentation: http://wsw.com/webcast/rrshq25/oncs. An
archived version of the webcast will be available for 90 days on
OncoSec's website: http://www.oncosec.com.
This conference brings together growth companies and a vast
audience of financial and strategic investors for in-depth
corporate presentations, as well as to facilitate one-on-one
investor and networking meetings. For more information, please
visit: http://www.rodm.com.
Second Annual Global Summit on Practical and Emerging Trends
in Melanoma
Dr. Pierce will present a lecture entitled:
"Reversing Immune Tolerance through Intratumoral Gene
Electrotransfer" during the "Emerging Technologies" session at the
Second Annual Global Summit on Practical and Emerging Trends in
Melanoma on September 19 starting at
11:15 AM PT at The Langham Hotel in
Pasadena, CA.
The focus of this summit is to translate the most recent
research and insights into patient care. Leaders will discuss the
evolution of the standard care in melanoma; advancing the care of
melanoma; integration of immune checkpoint inhibitors into the
treatment of melanoma; and new targets in melanoma. For more
information, please visit: http://www.omionc.com/melanoma2015.
European Cancer Congress 2015
Shailender Bhatia, MD, from the University of Washington School of Medicine and
principal investigator for OncoSec's Phase II Merkel cell carcinoma
trial, will present final results from this study in an oral
presentation entitled: "Intratumoral Delivery of Interleukin-12 DNA
via In Vivo Electroporation Leads to Regression of Injected and
Non-injected Tumors in Merkel Cell Carcinoma: Final Results of a
Phase II Study" at the European Cancer Congress on September 27 at 6:15 PM
CEST at the Messe Wien Exhibition & Congress Centre in
Vienna, Austria.
The European Cancer Congress (ECC2015) is a biennial meeting,
which combines the efforts of oncology professionals with the aim
of improving the prevention, diagnosis, treatment, and care of
cancer patients. It is the largest European platform for presenting
groundbreaking data to a global audience and the ideal environment
for participants to leverage knowledge, promote education, and
build awareness about oncology. For more information, please visit:
http://www.europeancancercongress.org/.
Sachs 15th Annual Biotech in Europe Forum
Punit Dhillon, President and CEO, will present a
corporate overview at the Sachs 15th Annual Biotech in Europe Forum
on September 30 at 11:30 AM CEST at the Congress Center Basel in
Basel, Switzerland. Mr. Dhillon
will also participate in an "Oncology III – Pharma/Biotech
BD&L" panel on September 30 at
2:00 PM CEST.
The forum provides an international stage for those interested
in investing and partnering in the biotech and life science
industry. The forum draws together a cross-section of early-stage,
late-stage and public companies with leading investors, analysts,
money managers and pharmaceutical licensing executives. Supported
and designed by leading figures within Europe's pharmaceutical and biotech industry,
this event will garner over 700+ delegates and 120+ presenting
companies. For more information, please visit:
http://www.sachsforum.com/.
About OncoSec Medical Incorporated
OncoSec is a
biopharmaceutical company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck
(HNSCC), and triple-negative breast cancer (TNBC). In addition to
ImmunoPulse™ IL-12, the company is also identifying and developing
new immune-targeting agents for use with the ImmunoPulse™ platform.
For more information, please visit www.oncosec.com.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-september-300136622.html
SOURCE OncoSec Medical Incorporated